Management and outcomes of myelomeningocele-associated 1

- hydrocephalus in low- and middle-income countries: a systematic 2
- review and meta-analysis protocol 3
- Berjo Dongmo Takoutsing^{1-2*}, Alvaro Yanez Touzet^{3*}, Jay J. Park⁴, Seong Hoon 4
- Lee⁵, Emily R. Bligh^{6,7}, Abdullah Egiz⁸, Conor S. Gillespie⁹, Anthony Figaii¹⁰⁻¹¹, On 5
- behalf of the Neurology and Neurosurgery Interest Group 6
- ¹Faculty of Health Sciences, University of Buea, Buea, Cameroon 8
- 9 ²Research Department, Association of Future African Neurosurgeons, Yaounde,
- Cameroon 10

7

- 11 ³School of Medical Sciences, Faculty of Biology, Medicine and Health, University of
- 12 Manchester, Manchester, United Kingdom
- 13 ⁴Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
- ⁵Academic Critical Care & Neurosurgery, Aberdeen Royal Infirmary, Aberdeen, 14
- 15 United Kingdom
- ⁶Surgical Specialties, The Queen Elizabeth University Hospital, Glasgow, United 16
- 17 Kingdom
- ⁷Academic Foundation Programme, The University of Glasgow, Glasgow, United 18
- 19 Kingdom
- 20 ⁸School of Medicine, University of Central Lancashire, Preston, United Kingdom
- ⁹Institute of Systems, Molecular and Integrative Biology, University of Liverpool, 21
- 22 Liverpool, United Kingdom
- ¹⁰Division of Paediatric Neuroscience (Neurosurgery), School of Child and 23
- Adolescent Health, University of Cape Town, Cape Town, South Africa 24
- 25 ¹¹Red Cross Children's Hospital, Klipfontein Road, 7700 Rondebosch, Cape Town,
- 26 South Africa

30

32

- 27 Correspondence to: Alvaro Yanez Touzet;
- 28 alvaro.yaneztouzet@student.manchester.ac.uk
- 29 *These authors contributed equally.
- PROSPERO registration number: CRD42021285850 31
- 33 WOF Chaptaki reposition for the research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Introduction: Hydrocephalus and myelomeningocele (MMC) place disproportionate burdens of disease on low and middle-income countries (LMICs). MMC-associated hydrocephalus and its sequelae result in a spectrum of severely devastating clinical manifestations, for which LMICs are disproportionately unprepared in terms of human, capital, and technological resources. This study aims to review and compare the management and outcomes of infant MMC-associated hydrocephalus in LMICs and high-income countries.

Methods and analysis: This systematic review and meta-analysis will follow the PRISMA 2020 guidelines. The following databases will be searched without restrictions on language, publication date, or country of origin: EMBASE, MEDLINE, The Cochrane Library, Global Index Medicus, African Journals Online, and SciELO. All peer-reviewed studies of primary data reporting management and outcomes of infant MMC-associated hydrocephalus will be included. Where high-quality homogeneous studies exist, meta-analyses will be conducted to compare the management and outcomes of MMC-associated hydrocephalus across socioeconomic and geographic regions of the world. The primary outcome will be treatment failure of the first-line hydrocephalus treatment, which we defined operationally as the performance of a second intervention for the same reason as the first. Secondary outcomes include time to failure, rates of mortality, and postoperative complications.

Ethics and dissemination: Ethical approval was not applicable because this study does not involve human participants. Dissemination strategies will include publication in a peer-reviewed journal, oral and poster presentations at conferences, and an interactive web application to facilitate interaction with the findings and promote the discussion and sharing of findings on social media.

PROSPERO registration number: CRD42021285850

Word count: 245

ARTICLE SUMMARY

66

67

68

69

70

71

73

74

77

78

79

80

81

82

85

Strengths and limitations of this study

- This review focuses on multiple treatment modes of a well-defined disease population.
- Six electronic databases that are commonly used across both high- and lowincome countries will be searched.
- 72 No restrictions on language, location, or publication date were placed during screening.
 - Unpublished studies will not be sought.
- 75 The representativeness of the sample will rely on the quality of reporting of 76 myelomeningocoele-associated hydrocephalus in the literature.
 - Only one operational definition of treatment failure—'the performance of a second intervention for the same reason as the first'—will be sought.
 - An interactive web application dashboard will be developed to facilitate the transparent interaction with our methods and findings and promote scientific discussion and scrutiny.
- **Keywords:** Systematic Review; Meta-Analysis; Hydrocephalus; Meningomyelocele; 83 84
 - Infant: Developing Countries: Outcome and Process Assessment, Health Care

INTRODUCTION

Hydrocephalus places a disproportionate burden of disease on low- and middle-income countries (LMICs) (1, 2). It affects approximately 1 in 1,000 infants worldwide, but its incidence may exceed 200,000 cases per year in developing regions like sub-Saharan Africa (3). Myelomeningocele (i.e., meningomyelocele or open spina bifida; MMC) is a common and severe spinal aetiology and constitutes a significant proportion of this population (4-6). Its prevalence also varies by geography but approximates 113 cases per 100,000 births in LMICs (7, 8), reaching 77–610 and 700 cases per 100,000 births in South Africa and Nigeria, respectively. These disorders result in a spectrum of clinical manifestations, among which MMC-associated hydrocephalus is one of the most common and debilitating (4, 9, 10).

In LMICs, the incidence of MMC-associated hydrocephalus is high and can affect as many as 75% of cases (11, 12). Times to diagnoses and treatment are often delayed in these settings and, if treatment is not promptly initiated, most patients do not survive beyond infancy (4). Treatment may involve surgery, which is prone to significant morbidity and mortality, particularly in low-resource settings (1, 3). Intervening at the earliest stage with the best possible treatment remains, therefore, a crucial step in the management of MMC-associated hydrocephalus.

Ventriculoperitoneal (VP) shunts are the current standard of treatment in LMICs (1). Increasingly, patients are being treated with endoscopic third ventriculostomy (ETV) or combinations of ETV and choroid plexus cauterization (CPC), whose success rates and perceptions are variable (1, 3, 4, 9). Although ETV/CPCs were first developed and validated in LMICs as the primary management for MMC-associated hydrocephalus, there remains limited aggregated data regarding their outcomes in the very countries these procedures were developed in. As such, the practice and outcomes of these techniques in LMICs warrant systematic review and meta-analysis. Previous work has examined the management and outcomes of hydrocephalus in HICs and LMICs (13, 14) albeit in unstratified medical subject headings (MeSH) age groups and aetiologies.

STUDY AIMS AND OBJECTIVES

Aim

119 This study aims to review and compare the management and outcomes of MMC-

associated hydrocephalus in infants across countries and treatment modes.

Objectives

121

122

130

131

135

146

147

148

149

150

151

152

- 123 To review and compare:
- 124 1. The first- and second-line use of VP shunts, combinations of ETV and CPC, 125 and conservative management;
- The rates and times to treatment failure of VP shunts, combinations of ETV and
 CPC, and conservative management; and
- 3. Measures of mortality and postoperative complications of VP shunts, combinations of ETV and CPC, and conservative management.

Review questions

- 132 Primary question:
- 133 1. What are the rates of failure of VP shunts, ETV, combinations of ETV and CPC, and conservative treatments in infant MMC-associated hydrocephalus?
- 136 Secondary questions:
- 2. What are the most frequent first- and second-line treatments in the management of infant MMC-associated hydrocephalus?
- 3. What is the time to failure of VP shunts, ETV, combinations of ETV and CPC, and conservative treatments in infant MMC-associated hydrocephalus?
- 4. What are the mortality and postoperative complication rates of VP shunts, ETV,
 combinations of ETV and CPC, and conservative treatments in infant MMC associated hydrocephalus?
- 5. Are the management and outcomes of the MMC associated with the failure of the hydrocephalus treatment?
 - Subgroup analyses by country and treatment mode are planned (further details in **Methods** section). The primary outcome will be the rate of treatment failure of the first-line hydrocephalus treatment. Secondary outcomes include: time to failure, rates of mortality, and postoperative complications. Operational definitions of outcomes are provided in the **Methods**.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Due to its historical standing as the local standard of treatment, our principal hypothesis is that: H₁: VP shunts have the lowest rates of treatment failure in the infant MMCassociated hydrocephalus population. Secondary hypotheses include: H₂: VP shunts are the most frequently used first-line treatment and have the lowest mortality and complication rates. H₃: Resource constrained environments are associated with late/worse MMC presentation amongst infants H₄: Late/worse MMC presentation is associated with high MMC treatment failure, mortality, and complication rates. H₅: MMC complication rates are associated with hydrocephalus treatment failure, mortality, and complication rates. **METHODS** This systematic review will be conducted following the guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement (15). Search A search strategy was developed to identify research articles on MMC-associated hydrocephalus. This was adapted from McCarthy et al., 2019, and consisted of synonyms of 'hydrocephalus' and 'myelomeningocele' (Supplementary Table 1). The search was run on the following electronic databases, from inception until 5 October 2021: EMBASE, MEDLINE, The Cochrane Library, Global Index Medicus, African Journals Online, and ScieLO. No restrictions on language, location, or publication date were placed, and unpublished studies will not be sought. Searches in all databases will be re-run prior to final analysis. Study selection Types of studies We will include articles published in peer-reviewed journals with any of the following designs: original research, trials, cross-sectional and cohort studies, multiple case reports (i.e., >1 case), and case series. Opinion pieces, comments, letters, guidelines, editorials, single-case reports, reviews, meta-analyses, and qualitative studies will be excluded, as well as articles published in non-peer-reviewed journals.

Country income level

We will include studies whose data were collected in low-, lower-middle-, upper-middle-, and high-income economies, according to the World Bank Country and Lending Groups (16). Studies from high-income economies will be used as comparators. Studies whose data cannot be traced to one particular country will be excluded.

Types of participants

All studies of infants aged 2 years or younger with a clinical or imaging diagnosis of MMC-associated hydrocephalus will be included. Non-infants (i.e., >2 years) will be excluded, as will infants with diagnoses of lipomyelomeningocoele, spina bifida occulta, or unspecified spina bifida, regardless of association with hydrocephalus.

Types of interventions

Studies of infants who have undergone either surgical or conservative treatment for hydrocephalus will be included. Surgical treatment includes VP shunting, ETV, combined ETV and CPC, combined VP shunting and ETV, and combined VP shunting, ETV, and CPC. We defined conservative treatment as non-surgical medical or pharmacological treatment. Studies of infants who underwent treatment for MMC, but not hydrocephalus, will be excluded, as will patients who received neither surgical nor conservative interventions.

Types of outcome measures

We will include studies of primary data reporting measures of treatment failure. In this review, treatment failure will be operationally defined as the performance of a second intervention for the same reason as the first. Studies reporting measures of mortality, morbidity, postoperative complications, and follow-up duration will also be included for secondary analysis. Post-operative complications will be defined as the unfavourable result of an intervention that did not result in treatment failure, and mortality as either 'intra-operative', if death occurred during a procedure, or 'perioperative', if it occurred

within 30 days of surgery. For conservative treatments, mortality will encompass

deaths that occurred within 30 days of administration.

Outcomes

- The primary outcome of our study will be the rate of treatment failure for the first-line hydrocephalus treatment. Secondary outcomes will include time to failure, rates of mortality, and postoperative complications.
- Study selection
- Search results will be uploaded to Rayyan (https://www.rayyan.ai) to facilitate deduplication and independent, blinded screening (17). First, titles and abstracts will be screened by two independent reviewers against the inclusion criteria, and the eligibility of the selected abstracts will be determined by reading the full texts. Unless otherwise stated, conflicts will be resolved through discussion and, where consensus cannot be achieved, through arbitration by the senior author (AF).

Data extraction

Two reviewers will independently extract and check the data extracted from the included studies using a standardised extraction proforma in Google Sheets (Supplementary Table 2). Any disputes will be settled by a third reviewer (BDT, AYT, or AF). Data items will include information on study and sample characteristics; vertebral level of MMC and aetiology of hydrocephalus; clinical presentation and method of diagnosis; treatment mode, timing, and follow-up; and primary and secondary outcomes. If data is insufficiently provided in the full text, we will contact the corresponding author to request for the missing information and wait up to two months for a response. Following correspondence, all available data will be reported and studies with missing data will not be eligible for inclusion in the meta-analysis. All data will be recorded and stored in a spreadsheet.

Risk of bias assessment

Included studies will be assessed for risk of bias by two independent reviewers of the extraction team. Randomised studies will be assessed using Version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2) (18). Non-randomised studies will be assessed using the ROBINS I tool (19). Risk of bias assessment will be used

during the analysis and results presented in terms of the primary and secondary objectives of this study.

Data analysis

Following extraction, data will be transferred to Python for analysis. Screening results will be presented using a PRISMA flow diagram. Study and sample characteristics will then be summarised using descriptive statistics; these may include: vertebral level of MMC; aetiology of hydrocephalus; method of diagnosis; treatment mode; indication for surgery (if surgical management); timing, and follow-up; and primary and secondary outcomes.

The use, failure, and mortality measures of VP shunts, combinations of ETV and CPC, and conservative management will then be meta-analysed. Although meta-analyses are planned, these will only become apparent after data extraction is complete. Publication bias will be assessed through the use of funnel plots and Egger's test (20). If asymmetry is found in the funnel plot, the Trim-and-Fill method will be used to account for any potential publication bias (21). The overall estimates and 95% confidence intervals will be obtained using random-effects models as per established methods (22). Cochran's Q test (P < 0.10) and the I² statistic will be used to assess heterogeneity among studies (23). Unless otherwise stated, the statistical significance will be set at P < 0.05, and comparisons to high-income economies will be drawn.

Mortality, failure, and complication rates will however vary with hydrocephalus aetiology, age, mode of treatment, characteristics of MMC, socioeconomic region and, crucially, duration of follow-up. Therefore, subgroup analyses will be sought, as appropriate, and particular care will be taken when interpreting failure between shunt placement and endoscopic treatments, owing to contrasting patterns of failure over the shorter and longer terms. A combination of dichotomous, proportion, continuous, O–E, and variance meta-analyses are planned for this purpose, as appropriate, depending on the data, and may include a potential subgroup analysis of the primary outcome into short-term rates and long-term rates. Recognising that case reports may present unusual and/or protracted outcomes, and randomised trials may assess active interventions improving outcomes, analyses by study design are also planned.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

DATA AVAILABILITY STATEMENT

Strength of body of evidence The confidence in cumulative evidence included in this review will be assessed using the GRADE approach. Two independent reviewers will use the GRADEpro Guideline Development Tool (GRADEpro GDT) to assess the quality of outcomes of this study. A third reviewer (BDT, AYT, or JJP) will settle disagreements. **Ethics and dissemination** Ethics approval for this study was not applicable because this study did not involve human participants. Dissemination strategies will include publication in a peerreviewed journal, oral and poster presentations at conferences, and an interactive web application to facilitate interaction with the findings and promote the discussion and sharing of findings on social media. Patient and public involvement None **ACKNOWLEDGEMENTS** We thank Moniba Korch, Brian Ou Yong Ming, and Safia Farsana Shabeer for their contributions during the development and piloting of the extraction proforma. **AUTHOR CONTRIBUTIONS** BDT, AYT, and AF were responsible for conceiving the article. AF is the guarantor. BDT, AYT, JJP, and CG wrote the manuscript. AE, AF, BDT, AYT, CG, ERB, JJP, and SHL provided a critical appraisal of the manuscript. All authors critically revised and approved the final manuscript. BDT and AYT contributed equally and are joint first authors of the manuscript. **ETHICS APPROVAL** Ethics approval for this study was not applicable because this study did not involve human participants.

All data relevant to the study are included in the article or uploaded as supplementary 322 information. 323 324 **FUNDING** 325 326 This work did not receive any funding. 327 **COMPETING INTERESTS** 328 329 None declared.

REFERENCES

- 333 Muir RT, Wang S, Warf BC. Global surgery for pediatric hydrocephalus in the
- 334 developing world: a review of the history, challenges, and future directions. Neurosurg Focus.
- 335 2016;41(5):E11.

330

331 332

- 336 Weiss HK, Garcia RM, Omiye JA, Vervoort D, Riestenberg R, Yerneni K, et al. A
- 337 Systematic Review of Neurosurgical Care in Low-Income Countries. World Neurosurg X.
- 338 2020;5:100068.
- 339 Kahle KT, Kulkarni AV, Limbrick DD, Jr., Warf BC. Hydrocephalus in children. Lancet.
- 340 2016;387(10020):788-99.
- 341 McCarthy DJ, Sheinberg DL, Luther E, McCrea HJ. Myelomeningocele-associated
- 342 hydrocephalus: nationwide analysis and systematic review. Neurosurg Focus. 2019;47(4):E5.
- 343 5. Oumer M, Taye M, Aragie H, Tazebew A. Prevalence of Spina Bifida among Newborns
- 344 in Africa: A Systematic Review and Meta-Analysis. Scientifica (Cairo). 2020;2020:4273510.
- 345 Njamnshi AK, Djientcheu Vde P, Lekoubou A, Guemse M, Obama MT, Mbu R, et al.
- 346 Neural tube defects are rare among black Americans but not in sub-Saharan black Africans:
- 347 the case of Yaounde - Cameroon. J Neurol Sci. 2008;270(1-2):13-7.
- 348 Lo A, Polšek D, Sidhu S. Estimating the burden of neural tube defects in low- and 7.
- 349 middle-income countries. J Glob Health. 2014;4(1):010402.
- 350 Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H, Mulinare J, et al. Describing
- the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. PLoS One. 351
- 352 2016;11(4):e0151586.
- 353 Ntimbani J, Kelly A, Lekgwara P. Myelomeningocele - A literature review.
- 354 Interdisciplinary Neurosurgery. 2020;19:100502.
- 355 de Paul Djientcheu V, Njamnshi AK, Wonkam A, Njiki J, Guemse M, Mbu R, et al.
- 356 Management of neural tube defects in a Sub-Saharan African country: the situation in
- 357 Yaounde, Cameroon. J Neurol Sci. 2008;275(1-2):29-32.
- 358 Dewan MC, Rattani A, Mekary R, Glancz LJ, Yunusa I, Baticulon RE, et al. Global
- 359 hydrocephalus epidemiology and incidence: systematic review and meta-analysis. J
- 360 Neurosurg. 2018:1-15.
- 361 Mnguni MN, Enicker BC, Madiba TE. A perspective in the management of
- myelomeningocoele in the KwaZulu-Natal Province of South Africa. Childs Nerv Syst. 362
- 363 2020;36(7):1521-7.
- 364 Ben-Israel D, Mann JA, Yang MMH, Isaacs AM, Cadieux M, Sader N, et al. Clinical
- outcomes in pediatric hydrocephalus patients treated with endoscopic third ventriculostomy 365
- 366 and choroid plexus cauterization: a systematic review and meta-analysis. J Neurosurg Pediatr.
- 367 2022:1-13.
- 368 14. Pande A, Lamba N, Mammi M, Gebrehiwet P, Trenary A, Doucette J, et al. Endoscopic
- third ventriculostomy versus ventriculoperitoneal shunt in pediatric and adult population: a 369
- systematic review and meta-analysis. Neurosurg Rev. 2021;44(3):1227-41. 370
- 371 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 372
- 373 2021;372:n71.
- 374 World Bank Data Help Desk. World Bank Country and Lending Groups 2022 [Available 16.
- 375 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-
- 376 country-and-lending-groups.

- 377 17. Rayyan – Intelligent Systematic Review 2022 [Available from: Rayyan.
- 378 https://www.rayyan.ai/.
- 379 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
- 380 revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:14898.
- Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. 381
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 382
- 383 2016;355:i4919.
- 384 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
- 385 simple, graphical test. Bmj. 1997;315(7109):629-34.
- Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and 386
- recommendations based on a large database of meta-analyses. Medicine (Baltimore). 387
- 388 2019;98(23):e15987.
- 389 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
- 390 1986;7(3):177-88.

393

- 391 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- 392 analyses. Bmj. 2003;327(7414):557-60.